alfredo r. galassi - how to deal with very lvef: the last remaining option to improve survival in...
TRANSCRIPT
![Page 1: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/1.jpg)
EURO CTO CLUBKrakow 2016
8th Experts "Live"
CTO Workshop 2016Sept 30th – Oct 01st, 2016
Alfredo R. Galassi MD, FESC, FACC, FSCAI
Department of Clinical and Experimental MedicineUniversity of Catania, Italy
How to deal with very LVEF: the last
remaining option to improve survival in
specific conditions
![Page 2: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/2.jpg)
Indications of CTO revascularization
Galassi et al, Eur Heart J 2015
![Page 3: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/3.jpg)
Potential time-dependent pathway of
dysfunctional myocardium
Wilcox JE et al, JACC 2015
![Page 4: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/4.jpg)
How to deal with CTO in patients with
depressed LVF
Are there clinical symptoms?
- Relief of angina and myocardial ischemia
- Relief of heart failure symptoms
Is the myocardium viable?
Could we increase prognosis?
PCI or CABG for CTOs in case of MVD?
![Page 5: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/5.jpg)
Case Summary
Clinical presentation: unstable angina + dyspnea NYHA III
Risk factors: smoker, diabetes type II, hypertension
2 D Echo:LVEF 24% midventricular inferolateral akinesia
global hypokinesia in the other segments
Target vessel: Mid RCA CTO
Septal collaterals from LAD and epicardial collaterals from LCx for RCA
Ostial LM stenosis Mid LAD stenosis
Ostial and proximal stenosis of OM2
62 year-old male
![Page 6: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/6.jpg)
Ventriculography
LVEF 20-25%
![Page 7: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/7.jpg)
Ischemia / Viability Assessment
Ischemia in LAD and RCA areas with
preserved viability
Stress/Perfusion Late Gadolinium
Inferolateral scar (distal segment)
![Page 8: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/8.jpg)
Treatment Strategy
Euroscore 6
Logistic Euroscore II 2.41%
Syntax score 35
J-CTO score for CTO lesion 3
Heart Team Decision Surgical revascularization
However the patient refused surgery
staged PCI was proposed
![Page 9: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/9.jpg)
RCA CTO revascularization
Double femoral 7Fr access
IABP Support
![Page 10: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/10.jpg)
Failed Initial Antegrade Approach
Finecross (Terumo)
Fielder XT-R(Asahi)
1 DES implantation in proximal RCA
![Page 11: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/11.jpg)
1 DES implantation in LM
Retrograde Approach(Hybrid Approach)
![Page 12: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/12.jpg)
Retrograde Approach(Hybrid Approach)
Retrogradely
Corsair (Asahi)
Sion (Asahi)
Antegradely
Finecross (Terumo)
Fielder XT-R(Asahi)
![Page 13: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/13.jpg)
Retrogradely
Corsair (Asahi)
Sion (Asahi)
Antegradely
Finecross (Terumo)
Fielder XT-R (Asahi)
Stent Facilitated Reverse CART Technique
Retrograde Approach(Reverse CART technique)
![Page 14: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/14.jpg)
Angiographic Final Result
3 DES implantation
![Page 15: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/15.jpg)
LAD PCI
1 DES implantation
![Page 16: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/16.jpg)
Optimization of LM stenting by IVUS
![Page 17: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/17.jpg)
Follow-upUneventful 6 month follow-up period
No angina, dyspnea (from NYHA III to NYHA II)
Baseline
LVEF 24%
At 6 months
LVEF 36%
![Page 18: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/18.jpg)
Ventriculography
Baseline At 6 months
LVEF 24% LVEF 36%
![Page 19: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/19.jpg)
Systematic Angiographic Control(6 months)
Intra-stent focal restenosis of mid RCA
Good result on LM and LAD
Stenosis of ostial and proximal OM 2 previously left untreated
![Page 20: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/20.jpg)
PCI of RCA
1 DES implantation
![Page 21: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/21.jpg)
PCI of LCx
Complete revascularization was attained
1 DES implantation
![Page 22: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/22.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 23: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/23.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 24: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/24.jpg)
Viability / Ischemia Assessment
Preserved LVEF Impaired LVEF
CTO territory
Necrotic or ischemic non-CTO related territory
Symptoms
QOLPrognosis
Symptoms
QOL
Prognosis
![Page 25: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/25.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 26: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/26.jpg)
Hemodynamic Support and More
Use of LV support devices is recommended
Need for hemodynamic support is mandatory in
“retrograde approach (use of donor arteries and
collaterals)
Do not hesitate to use temporary pacing
Subset of patients unable to tolerate complications
(minor pericardial leakage due to coronary perforation
may result in cardiogenic shock)
![Page 27: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/27.jpg)
Hemodynamic Support
![Page 28: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/28.jpg)
Hemodynamic Support and More
Use of LV support devices is recommended (IABP,
ECMO, Impella, Tandem Heart)
Need for hemodynamic support is mandatory in
“retrograde approach (use of donor arteries and
collaterals)
Do not hesitate to use temporary pacing
Subset of patients unable to tolerate complications
(minor pericardial leakage due to coronary perforation
may result in cardiogenic shock)
![Page 29: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/29.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 30: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/30.jpg)
Procedural Tips & Tricks
Example of possible accesses
- Right femoral: a guiding catheter for RCA
- Left femoral: IABP and pacing
- Right radial: a guiding catheter for LCA
Both antegrade and retrograde are feasible
If LVDd is 70mm, consider a retrograde short
guiding catheter to bring a retrograde 150cm Corsair
into an antegrade guiding catheter (even through
septal connections). When CTO is located in RCA,
right brachial approach is preferred for a retrograde
short guiding catheter into LCA
![Page 31: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/31.jpg)
Objective
To be less traumatic as possible
“Loose Tissue Tracking Concept”
by new soft double coil polymeric wires
![Page 32: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/32.jpg)
o
Galassi et al, Eur Heart J 2014
![Page 33: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/33.jpg)
Case Summary
Clinical Presentation: NSTEMI complicated by VF and cardiac arrest
67 year-old male
Risk Factors Smoker Diabetes type II Hypertension
2-D Echo: LVEF 18%
CTOs of 3 vessels (LAD, LCx, RCA)
Bad candidate for surgery(very low EF and small diseased vessels with poor distal visualization)
![Page 34: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/34.jpg)
PCI of RCA
Fielder XT-R (Asahi)
ECMO hemodynamic support
Baseline Final result
![Page 35: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/35.jpg)
PCI of LAD and LCx
Baseline Final resultFielder XT-R (Asahi)
ECMO hemodynamic support
![Page 36: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/36.jpg)
PCI of LAD and LCx
Fielder XT-R (Asahi)
ECMO hemodynamic support
![Page 37: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/37.jpg)
Follow-up
Uneventful 12-month follow-up period
Patient asymptomatic
Improvement of LVEF (from 18% to 35%)
at 6 month follow-up
![Page 38: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/38.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 39: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/39.jpg)
Revascularization Strategy
All non-CTO lesions need to be treated before hand
(consider viability)
Do not hesitate to consider staged revascularization
strategy in two procedures
Revascularization strategy should be functional
deriving from viability/ischemia assessment
In presence of multiple CTOs:
- Start with the “easiest” CTO lesion (J-CTO score)
- 1 CTO lesion/procedure (might facilitate other CTO treatment
by increase collateral flow, better distal visualization, better
tollerance to CTO
![Page 40: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/40.jpg)
Sohn et al. J Korean Med Sci 2014
![Page 41: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/41.jpg)
Généreux et al. Am J Cardiol 2014
SRI = SYNTAX Revascularization Index
SRI=100% (complete revascularization),
SRI<100% to 50%, and SRI <50%
![Page 42: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/42.jpg)
CTO PCI in patients with MVD and low EF
1. Viability / Ischemia assessment
2. Hemodynamic support during PCI
3. Procedural Tips & Tricks
4. Complete vs. Incomplete revascularization
5. Follow-up
![Page 43: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/43.jpg)
During In-hospital Stay
Multidisciplinary team
Fragile patients requiring careful attention
and monitoring
Control of comorbidities ++++
- Diabetes
- Infections
- Electrolytes
![Page 44: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/44.jpg)
Close clinical controls at 1, 3, 6, 12 months
We recommend systematic angiographic
control
- High rate of asymptomatic re-stenosis
- Long stented segments
- Susceptibility to any further ischemic events
Control of comorbidities ++++
Follow-up
![Page 45: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/45.jpg)
From January 2013 to December 2015839 CTO patients attempted percutaneously
LVEF≥50%552 patients (65.8%)
LVEF 35-50%215 patients (25.6%)
LVEF≤35%72 patients (8.6%)
Successful CTO PCI66 patients (91.7%)
Failed CTO PCI6 patients (8.3%)
Clinical follow-up66 patients (100%)17.6±10.2 months
Angiographic follow-up49 patients (74.2%)
Flow ChartMulticentric Prospective Study
![Page 46: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/46.jpg)
All 839 patients
LVEF≥50%552 patients
(Group 1)
LVEF 35-50%215 patients
(Group 2)
LVEF≤35%72 patients(Group 3)
Age, years, mean ± SD 64.6 ± 10.5 63.8 ± 10.2 65.8 ± 11.3* 66.4 ± 10
Age ≥ 75 years, n (%) 163 (19.4) 85 (15.4) 58 (27)* 20 (28.8)†
Males, n (%) 736 (87.7) 475 (86.1) 195 (90.7) 66 (91.7)
Diabetes, n (%) 252 (30) 152 (27.5) 67 (31.2) 33 (45.8)†‡
Smokers, n (%) 447 (53.3) 289 (52.4) 116 (54) 42 (58.3)
Hypertension, n (%) 695 (82.8) 455 (86.1) 179 (83.3) 61 (84.7)
Dyslipidemia, n (%) 607 (72.3) 385 (69.7) 174 (80.9)* 48 (66.7)†‡
BMI , kg/m2 , mean ±SD 28.6 ± 4.5 28.6 ± 4.5 28.9 ± 4.4 27.3 ± 4.2‡
Peripheral artery disease, n (%) 129 (15.4) 66 (12) 46 (21.4)* 17 (23.6)†
Chronic kidney disease, n (%) 130 (15.5) 68 (12.3) 44 (20.5)* 18 (25)†
Prior MI, n (%) 358 (42.7) 197 (35.7) 118 (54.9)* 43 (59.7)†
Prior PCI, n (%) 287 (34.2) 186 (33.7) 84 (39.1) 17 (23.6)‡
Prior CABG, n (%) 141 (16.8) 77 (13.9) 50 (23.3)* 14 (19.4)
Prior stroke, n (%) 13 (1.5) 6 (1.1) 5 (2.3) 2 (2.8)
Three-vessel disase, n (%) 370 (44.1) 211 (38.2) 117 (54.4)* 42 (58.3)†
> 1 CTO, n (%) 40 (4.7) 18 (3.2) 13 (6.9)* 9 (12.5)†
* Group 1 vs. Group 2, p<0.05 / † Group 2 vs. Group 3, p<0.05 / ‡ Group 1 vs. Group 3, p<0.05
Clinical characteristics
![Page 47: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/47.jpg)
All 839 patients
LVEF≥50%552 patients
(Group 1)
LVEF 35-50%215 patients
(Group 2)
LVEF≤35%72 patients(Group 3)
Target CTO artery, n (%)LADLCxRCA
222 (26.5)123 (14.7)494 (58.9)
151 (27.4)76 (13.9)
325 (58.9)
55 (25.6)30 (14)
130 (60.4)
16 (22.2)17(23.6)39 (54.2)
Blunt Stump, n (%) 506 (60.3) 330 (59.8) 126 (58.6) 50 (69.4)
Bending >45°, n (%) 265 (31.6) 180 (32.6) 64 (29.8) 21 (29.2)
Severe Calcifications, n (%) 234 (27.9) 155 (28.1) 59 (27.4) 20 (27.8)
CTO length, mm, mean ± SD 42.2 ± 29.2 42.6± 29.6 42.5 ± 29 39 ± 27.3
CTO length ≥20mm, n (%) 674 (80.3) 441 (79.9) 179 (83.3) 56 (77.8)
Ostial location, n (%) 111(13.2) 68 (12.3) 31 (14.4) 48 (66.7)
In-stent CTO, n (%) 56 (6.7) 33 (6) 15 (7) 8 (11.1)
Previous attempt, n (%) 255 (30.4) 190 (34.4) 49 (22.8) 16 (22.2)†
Collateral filling Rentrop 2-3, n (%) 574 (68.4) 388 (70.3) 148 (68.8) 38 (52.8)†‡
J-CTO score ≥3, n (%) 402 (47.9) 273 (49.5) 97 (45.1) 32 (44.4)
ORA score ≥3, n (%) 103 (12.3) 53 (9.6) 35 (16.3)* 15 (20.8)†
Angiographic characteristics
* Group 1 vs. Goup 2, p<0.05 / † Group 2 vs. Goup 3, p<0.05 / ‡ Group 1 vs. Goup 3, p<0.05
![Page 48: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/48.jpg)
0
20
40
60
80
100
All LVEF ≥50% LVEF 35-50% LVEF ≤ 35%
93.6 93.5 94.491.7
Su
ccess
rate
(%
)All p=NS
Procedural Success
![Page 49: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/49.jpg)
0%
20%
40%
60%
80%
100%
All LVEF ≥50% LVEF 35-50% LVEF ≤ 35%
Retrograde only Hybrid Antegrade only
55.9 55.1 59.551.4
19.414.41917.9
26.2 25.9 26.1 29.2
All p=NS
Recanalization Techniques
![Page 50: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/50.jpg)
0%
20%
40%
60%
80%
100%
All LVEF ≥50% LVEF 35-50% LVEF ≤ 35%
Dissection reentry True to True lumen
28.9 25.436.4 33.3
71.1 74.6
64.6 66.7
All p=NS
Recanalization Techniques
![Page 51: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/51.jpg)
All 839 patients
LVEF≥50%552 patients
(Group 1)
LVEF 35-50%215 patients
(Group 2)
LVEF≤35%72 patients(Group 3)
Procedural Time, min, mean ± SD 118.1 ± 75.5 119 ± 75.3 118.1 ± 79.2 110.5 ± 61.9
Fluoroscopy time, min, mean ± SD 57.1 ± 39.2 57 ± 38.2 57.9 ± 43 54.8 ± 35.3
Contrast Load, ml, mean ± SD 358 ± 206.5 369.9 ± 213.9 349.1 ± 197.7 295.6 ± 159 †‡
Radiation Dose, mGy, mean ± SD3497.2 ± 2539 3578.8 ± 2574.6 3341.9 ± 2299.4 3335.3 ± 2854.6
* Group 1 vs. Goup 2, p<0.05† Group 2 vs. Goup 3, p<0.05‡ Group 1 vs. Goup 3, p<0.05
Procedural Details
![Page 52: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/52.jpg)
All 839 patients
LVEF≥50%552 patients
(Group 1)
LVEF 35-50%215 patients
(Group 2)
LVEF≤35%72 patients(Group 3)
Coronary Perforation, n (%) 34 (4) 25 (4.5) 6(2.8) 3 (4.2)
Tamponade, n (%) 13 (1.5) 8 (1.4) 5 (2.3) 0
Death, n (%) 0 0 0 0
Non Q wave MI, n (%) 7 (0.8) 3 (0.5) 4 (1.9) 0
Q wave MI, n (%) 2 (0.2) 2 (0.4) 0 0
Stent thrombosis, n (%) 2 (0.2) 1 (0.2) 1 (0.5) 0
Stroke, n (%) 0 0 0 0
Need for emergency CABG, n (%) 1 (0.1) 1 (0.2) 0 0
All p=NS
Immediate Outcomes
![Page 53: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/53.jpg)
CTO Patients with EF<35%
LV assistance device
62pts86.2%
10pts13.8%
No LV assistance device LV assistance device
8 2
IABP ECMO
![Page 54: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/54.jpg)
Patients CTO Patients with EF<35%successfully revascularized
Improvement in LVEF
29.1
41.6
0
10
20
30
40
50
before CTO PCI after CTO PCI
FU 17.6 ± 10.2 months
P<0.001
Range
(17 – 34)
%
![Page 55: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/55.jpg)
1
0.8
0.6
0.4
0.2
0
0 6 12 18 24 30 36
MA
CC
E f
ree s
urv
ival
Follow-up (months)
Patients(N=49)
Restenosis, n (%) 4 (8.2)
Focal Restenosis, n (%), 4 (8.2)
Diffuse Restenosis, n (%) 0
Re-occlusion, n (%) 0
CTO Patients with EF<35%
Clinical Outcome
No impact of LV assistance device use
![Page 56: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/56.jpg)
Take Home Messages
In experienced hands, CTO PCI is efficient and
safe in patients with low EF<35%
PCI in very low LVEF patients is very often the
last «chance»
Successful CTO PCI might improve
- LVEF
- Clinical outcome +++
![Page 57: Alfredo R. Galassi - How to deal with very LVEF: the last remaining option to improve survival in specific conditions](https://reader031.vdocument.in/reader031/viewer/2022030315/587ae25d1a28ab542b8b6a0b/html5/thumbnails/57.jpg)
Thank You
For Your Attention
www.alfredogalassi.com